The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

  ()
Shares of Biogen Inc. soared after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings. read more >

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis

Research Report
  ()
The details of this study and a second one are outlined in a ROTH Capital Partners report. read more >

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

  ()
Dermira shares traded higher after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. read more >

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

  ()
Shares of Protalix Biotherapeutics skyrocketed on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. read more >

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer

  ()
Shares of Achillion Pharmaceuticals traded much higher after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. read more >

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

  ()
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. read more >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

  ()
Shares of Relmada Therapeutics traded wildly after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher and the stock was halted several times trading due to extreme price volatility. read more >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

  ()
Shares of Cerecor Inc. traded higher after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. read more >

Technical Analyst Expects Health Technologies Firm to Break Higher

Contributed Opinion
  ()
Technical analyst Clive Maund outlines the reasons this stock might break higher. read more >

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights

  ()
Shares of Reata Pharmaceuticals traded 12% higher after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. read more >

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

  ()
Shares of Ra Pharmaceuticals doubled after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. read more >
News Update

Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial

News Update
  ()
Data from this study should be released by the end of this year. read more >

Coverage Initiated on U.S.-Based Precision Therapy Developer

Research Report
  ()
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. read more >

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%

  ()
Akcea Therapeutics' shares rose 30% on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. read more >

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

  ()
PDS Biotechnology Corp. shares traded 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. read more >

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer

  ()
Shares of Dova Pharmaceuticals rose 38% on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. read more >

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

Research Report
  ()
The latest clinical trial results are dissected in a ROTH Capital Partners report. read more >

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

  ()
Shares of Aravive Inc. traded higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. read more >

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

  ()
Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. read more >

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials

  ()
The Medicines Company's shares traded 8.5% higher after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hypercholesterolemia, which leads to high levels of LDL-C, and one for atherosclerotic cardiovascular disease. read more >

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

  ()
The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. read more >

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

  ()
Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. read more >

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'

Research Report
  ()
The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. read more >

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study

  ()
Avadel Pharmaceuticals' shares trades 30% higher on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. read more >

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

  ()
Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Products for Human Use also adopted a positive opinion for Dupixent in a third indication. read more >
Showing Results: 1 to 25 of 112 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe